Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01998828 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
A Phase 2 study, sponsored by Sierra Oncology LLC - a GSK company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT01998828 is a Phase 2 study that was terminated before completion, run by Sierra Oncology LLC - a GSK company. The registered enrollment target is 39 participants.
The verdict
NCT01998828, a Phase 2 study, was terminated before completion, sponsored by Sierra Oncology LLC - a GSK company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
This open-label study is to determine the safety and efficacy of momelotinib in participants with either polycythemia vera (PV) or essential thrombocythemia (ET) who have not yet received treatment with a Janus kinase (JAK) inhibitor.
Interventions
- DRUG Momelotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2014-02-19 |
| Est. Completion | 2015-05-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01998828
The ClinicalTrials.gov registry entry for NCT01998828 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sierra Oncology LLC - a GSK company, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Momelotinib is the first listed.
NCT01998828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01998828 about?
NCT01998828 is a clinical study titled "Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia". This open-label study is to determine the safety and efficacy of momelotinib in participants with either polycythemia vera (PV) or essential thrombocythemia (ET) who have not yet received treatment with a Janus kinase (JAK) inhibitor.
What is the current status of trial NCT01998828?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2014-02-19. Estimated completion is 2015-05-07.
What interventions are being tested in trial NCT01998828?
The interventions under investigation include: Momelotinib (DRUG).
Who is sponsoring clinical trial NCT01998828?
This trial is sponsored by Sierra Oncology LLC - a GSK company, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.